Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, and valuation discounts.

By Amina Niasse and Mariam Sunny (Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.

CleanSpark appears to be an attractive investment and the potential upside could be as high as 2x.

June 26 (Reuters) - Novo Nordisk (NOVOb.CO) said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy, starting July 1.

India Business News: Novo Nordisk has launched Wegovy in India, an anti-obesity drug aimed at managing weight and reducing cardiovascular risks. Priced between Rs 17,345 a ...

Novo Nordisk is ending its partnership with Hims & Hers due to concerns over its practices related to compounded GLP-1s.

Novo Nordisk's U.S.-listed shares fell close to 6% Monday after the drugmaker revealed the latest results for a new weight-loss treatment.

Novo Nordisk abruptly ended its partnership with Hims & Hers after the Danish drugmaker accused the telehealth company of illegally selling cheaper copycats of Novo Nordisk’s weight-loss drug ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the weight-loss drug.

Novo began collaborating with Hims & Hers and other telehealth companies to boost Wegovy sales once the FDA declared the shortages over earlier this year, putting pharmacies on notice to stop ...

COPENHAGEN (Reuters) -Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging ...